Clinical Trial Update: A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Lucitanib (VEGFR-FGFR-PDGFR inhibitor) in metastatic breast cancer was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lucitanib (Lucitanib)

Snippet

Sponsor: Clovis Oncology, Inc. | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-06-23